Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Dolutegravir / rilpivirine (Juluca®) is recommended as an option for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any nonnucleoside reverse transcriptase inhibitor or integrase inhibitor. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | dolutegravir / rilpivirine (Juluca®) | ||
| Formulation | 50 mg / 25 mg film-coated tablet | ||
| Reference number | 2850 | ||
| Indication | Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor |
||
| Company | ViiV Healthcare UK Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2218 | ||
| NMG meeting date | 07/11/2018 | ||
| AWMSG meeting date | 12/12/2018 | ||
| Date of issue | 19/12/2018 | ||
| Date of last review | April 2022 | ||
| Commercial arrangement | WPAS | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||